The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
Participants agreed to follow the individual physical activity intervention (IPAI)
Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
Participants with Internet access at home and email address
Pregnant participants or planning to become pregnant while enrolled in this study
Participants with inability or deemed unsafe to practice physical activity
Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
Participants who are currently involved in an interventional study